Lenacapavir, a twice-yearly injection, has FDA approval for HIV prevention in adults and adolescents. Clinical trials showed lenacapavir reduced HIV transmission risk by over 99.9 per cent. High expected cost of lenacapavir may limit global accessibility despite its efficacy
